Search
Now showing items 1-10 of 11
Developing Biomarkers for MS.
(2015)
Existing clinical outcomes of disease activity, including relapse rates, are inherently insensitive to the underlying pathological process in MS. Moreover, it is extremely difficult to measure clinical disability in patients, ...
The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis.
(2018-02)
BACKGROUND: The BRadykinesia Akinesia INcordination (BRAIN) test is an online keyboard-tapping test previously validated as a sensitive tool for detecting signs of Parkinson's disease. OBJECTIVES: To determine whether the ...
Vitamin D supplementation.
(2018-02)
Vitamin D testing and supplementation is of great interest to neurologists and their patients. Recommended nutritional intakes of vitamin D in the UK remain focused on bone health, despite increasing evidence for a role ...
No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation.
(2018-05)
BACKGROUND: Whilst the dangers of 'legal highs' have been widely publicised in the media, very few cases of the neurological syndrome associated with the inhalation of nitrous oxide (N2O) have been reported. Here we set ...
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
(2017-11)
BACKGROUND: Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be ...
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
(2017-09-12)
OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS: In the 2-year Comparison of Alemtuzumab and ...
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
(2018-05)
BACKGROUND: The mechanism of action of oral cladribine, recently licensed for relapsing multiple sclerosis, is unknown. OBJECTIVE: To determine whether cladribine depletes memory B cells consistent with our recent hypothesis ...
Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.
(2017-10)
BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
(2016-10)
There are several options for switching people with multiple sclerosis (MS) who are at high risk of developing progressive multifocal leukoencephalopathy (PML) from natalizumab to alemtuzumab. However, some of these have ...
